Sarcoma Research International
Rastogi S, Mishra SV and Aggarwal A. Overall Survival as Primary End Point in Advanced Soft Tissue
Advanced soft tissue sarcoma is extremely complex and heterogenous
disease with dismal outcomes. The advent of newer drugs like pazopanib,
trabectedin and most recently eribulin has enabled a flexible and more
individualized approach to the treatment of advanced soft tissue sarcoma.
However, given their modest benefit, it becomes essential to evaluate if we are
using appropriate end points in the current trials and how the equation between
progression free survival and overall survival might change in future.